- Tonix Pharmaceuticals Holding Corp TNXP received the official minutes from a Type B pre-Investigational New Drug Application (IND) meeting with the FDA.
- The meeting was related to TNX-102 SL1 (cyclobenzaprine HCl sublingual tablets) as a potential treatment for Long COVID Syndrome (Long COVID), which is now known officially as Post-Acute Sequelae of COVID-19 (PASC2).
- Related: Tonix Pharma To Test Its Fibromyalgia Candidate In Long COVID Syndrome.
- Tonix plans to submit the IND in Q4 of 2021 to support a Phase 2 study in a subset of Long COVID patients whose symptoms overlap with fibromyalgia.
- Also Read: IDMC Recommends Tonix Pharma To Stop Enrollment In Fibromyalgia Trial.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: TNXP shares are up 16.1% at $0.80 during the premarket session on the last check Tuesday.
TNXPTonix Pharmaceuticals Holding Corp
$15.61-1.58%
Edge Rankings
Momentum
10.74
Growth
-
Quality
-
Value
76.19
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
